Skip to main content
. 2024 Sep 25;7(9):e2435431. doi: 10.1001/jamanetworkopen.2024.35431

Figure 1. Prevalence of Emergent Nirmatrelvir Resistance Mutations in Untreated and Nirmatrelvir-Treated Individuals.

Figure 1.

Individuals treated with nirmatrelvir were also separated by immunosuppression (IS) and virologic rebound (VR) status. P values were calculated using a 2-sided Boschloo test.